TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Unilateral breast cancer~* Large operable breast cancer/LOBC (T3N0M0 or T3N1M0) and Locally advanced breast cancer/LABC (T3N1-2M0; T2N2M0)~* Age \<70 years~* Fit for CT~Exclusion Criteria:~* Prior IB or EB~* Metastatic breast cancer~* Renal failure or deranged RFT~* Hypoparathyroidism~* Pregnant or lactating mothers or women of childbearing age not practicing contraception~* Patient on any of the following drugs: Magnesium-containing antacids, Digitalis, Phenytoin barbiturates, Thiazide diuretics.~* Previous history of other cancers except cured skin and cervical carcinoma in situ.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- No additional treatment (Type: NO_INTERVENTION): No Injection Vit D3 or Injection Progesterone prior to chemotherapy cycle
- Inj. Proluton (Type: ACTIVE_COMPARATOR): Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
- Inj. Arachitol (Type: ACTIVE_COMPARATOR): Injection Arachitol (Vitamin D3) 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
- Inj. Proluton and Inj. Arachitol (Type: ACTIVE_COMPARATOR): Injection Arachitol (Vitamin D3) 300,000 I.U/ml IM and Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Multiparametric MRI for Prostate Cancer Localization and Characterization: New Methods

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* male patients diagnosed with T1C or T2 prostate cancer, awaiting prostatectomy~Exclusion Criteria:~* unable to give informed consent~* contraindication to MRI or MRI contrast agent~* claustrophobia~* renal impairment~* prior hormonal or radiation therapy for prostate cancer~* active prostatitis~* moderate to severe rectal inflammation~* previous rectal surgery~* prostate biopsy within 4 weeks of planned MRI

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm study (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Prescreened with targeted SNP on the same allele as the pathogenic CAG expansion~* Ambulatory, male or female patients aged ≥25 - ≤65 years~* Clinical diagnostic motor features of HD, defined as Unified Huntington's Disease Rating Scale (UHDRS) Diagnostic Confidence Score = 4~* Early manifest HD, Stage I or Stage II based on UHDRS Total Functional Capacity Scores ≥7 and ≤13~Key Exclusion Criteria:~* Malignancy or received treatment for malignancy, other than treated basal cell or squamous cell carcinoma of the skin, within the previous 5 years.~* Received investigational drug or implantable device in prior 3 months or investigational oligonucleotide in prior 6 months or 5 half-lives of the oligonucleotide, whichever is longer~* Clinically significant medical condition, unstable psychiatric symptoms, substance abuse, or pregnancy~* Inability to undergo brain MRI~* Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or unsuccessful lumbar puncture

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- WVE-120101 (Dose A) or placebo (Type: EXPERIMENTAL): None
- WVE-120101 (Dose B) or placebo (Type: EXPERIMENTAL): None
- WVE-120101 (Dose C) or placebo (Type: EXPERIMENTAL): None
- WVE-120101 (Dose D) or placebo (Type: EXPERIMENTAL): None
- WVE-120101 (Dose E) or placebo (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Repeated Voluntary Drug Intoxication (IMVr): Characterization of a New Addictive Behavior by Clinical Phenotyping and Functional Imaging

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Will be offered for study subjects that meet the following criteria:~* Man or woman hospitalized (e) in the aftermath of a IMV:~  * History of at least 2 for the IMV group IMVr~ * First suicide attempt high intentionality (SIS score\> 20/30) for group IMVS~* Man or woman with alcohol dependence according to DSM-IV-TR, in the aftermath of withdrawal (outpatient or inpatient) for the alcohol group~* Man or woman free from any addictive disorder, suicidal or mood for the control group~And all of the following criteria:~* Age greater than or equal to 18 and less than or equal to 60 years~* Informed consent in writing signed by the patient~* Person affiliated to the social security or beneficiary of such a scheme~Exclusion Criteria:~For IMVS Group:~* Have a history of scarification or addictive disorder (behavioral or product)~In the alcohol group:~* TS present history~For all patients, presenting at least one of the following criteria:~* Age less than 18 years, over 60 years.~* acute or chronic delusional disorder.~* Cognitive impairment or impeding the reading comprehension quizzes.~* secondary pathologies at a stroke.~* Denial of participation.~* Contraindications to MRI.~* Subjects with clinically significant gastrointestinal, renal, hepatic, endocrine, cardiovascular or respiratory (especially persistent asthma) which can prevent stay of 60 min in MRI without being hindered.~* No participant to another pharmacological study.~* unauthorized treatments: all psychotropic treatments (except anti-anxiety treatments benzodiazepine average duration of action and antihistamine), baclofen and other treatment can modify vasoreactivity fMRI.~* Coagulation disorders against-indicating blood.~* People under guardianship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Volunteers repeated drug poisoning (Type: EXPERIMENTAL): performing MRI and a biological assessment
- Volunteers single drug poisoning (Type: OTHER): performing MRI and a biological assessment
- alcoholic (Type: OTHER): performing MRI and a biological assessment
- volunteers (Type: OTHER): performing MRI and a biological assessment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rosuvastatin in Treating Women With Cardiovascular Complications Who Are Undergoing Chemotherapy For Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Women receiving therapy for breast cancer without a history of cardiovascular disease An low-density lipoprotein (LDL) cholesterol level of less than 160 mg per deciliter (3.4 MMol per liter) Willingness to participate for the duration of the trial (3 months) Written informed consent Triglyceride level of less than 500 mg per deciliter (5.6 mmol per liter)~Exclusion Criteria:~Previous or current use of lipid-lowering therapy Current use of postmenopausal hormone-replacement therapy Evidence of hepatic dysfunction (an alanine aminotransferase level that was more than twice the upper limit of the normal range) Creatine kinase level that was more than three times the upper limit of the normal range Creatinine level that was higher than 2.0 mg per deciliter (176.8 umol per liter) Diabetes Uncontrolled hypertension (systolic blood pressure \> 190 mm Hg or diastolic blood pressure \> 100 mm Hg) Uncontrolled hypothyroidism (a thyroid-stimulating hormone level that was more than 1.5 times the upper limit of the normal range) Recent history of alcohol or drug abuse or another medical condition that might compromise safety or the successful completion of the study Exclude patients with inflammatory conditions such as severe arthritis, lupus, or inflammatory bowel disease, and patients taking immunosuppressant agents such as cyclosporine, tacrolimus, azathioprine, or long-term oral glucocorticoids Pregnant women are excluded from participation in this study

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (rosuvastatin) (Type: EXPERIMENTAL): Patients receive rosuvastatin PO once daily for 3 months in the absence of disease progression or unacceptable toxicity.
- Arm II (placebo) (Type: PLACEBO_COMPARATOR): Patients receive placebo PO once daily for 3 months in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Role Of Empiric Dilation In Patients With Dysphagia With Normal Endoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients age: \> 18 years.~2. Outpatients undergoing EGD for dysphagia.~3. Ability to provide written informed consent.~Exclusion Criteria:~* Abnormal endoscopy (stricture, abnormal motility or mucosa observed)~* Oropharyngeal dysphagia suspected based on history and physical examination~* History of CVA or other neurologic disorder~* Known connective tissue disease (SLE, scleroderma, CREST, RA)~* Known histopathology based esophageal motor disorder, e.g. achalasia~* Prior thoracic or foregut surgery (excluding cholecystectomy)~* Prior thoracic radiation therapy~* Hiatus hernia \>2 cm as judged during EGD

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- dilation to 27 French (Type: PLACEBO_COMPARATOR): None
- Dilation of the esophagus to 54 French (Type: EXPERIMENTAL): Esophagus will be dilated with a Savory dilator

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Functional and Quality of Life Outcomes Following Viscosupplementation for Knee Osteoarthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 21 years of age or older~* osteoarthritis degeneration, degenerative joint disease or degeneration~* fully cognizant of study procedures~* willing to carefully participate in all study processes and assessments~Exclusion Criteria:~* less that 21 years of age~* allergic reactivity to hyaluronic acid~* current knee infection, infection around injection site or any skin disease~* pregnancy or lactation~* non-ambulatory

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Outcomes following viscosupplemantation (Type: None): Patients with documented knee osteoarthritis receiving viscosupplementation of the knee.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Vitamin B12 and Folic Acid on POCD in Elderly Non-cardiac Surgical Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Age equals or over 65~* 2. Scheduled for spinal or joint replacement surgery under general anesthesia，estimated surgery time over 2h.~* 3. Signed written informed consent obtained~* 4. Non-surgical Controls are age and sex - matched community elderly residents.~Exclusion Criteria:~* 1. Disease of the central nervous system that impairs cognitive function, including all kinds of dementia, and depression~* 2. MMSE score \< 24~* 3. Received education for less than 5 years~* 4. Currently taking sedative or antidepressant drugs~* 5. Has taken vitamin B12, folic acid or their derivatives (methycobalamin, cobalamin, tetrahydrofolic acid, etc.) within 6 months.~* 6. Has accepted cardiac or neurological surgery within one year.~* 7. Was admitted for other clinical trials within 3 month~* 8. Patients that regularly taking drugs that affect vitamin B absorption, including colchicine, neomycin, salicylate.~* 9. Has severe visual or auditory problems~* 10. Alcohol or drug dependent (alcohol dependent: drank more than 100 mL of Chinese liqueur with alcohol concentration over 40% everyday for the past 3 months).~* 11. Patients that are already admitted for this study can not be admitted the second time, no matter the cause of surgery

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VB12+FA (Type: EXPERIMENTAL): Patients will receive oral supplementation of 0.5mg methylcobalamin, 3/day and 5 mg folic acid, 1/day for 7 days before non-cardiac surgery.
- Placebo (Type: PLACEBO_COMPARATOR): Patients with receive oral tablets of placebo for folic acid 1/d and placebo for methylcobalamin 3/d, which look exactly like the interventional drugs as oral supplementation for 7 days before non-cardiac surgery.
- Non-surgical controls (Type: OTHER): Age and sex-matched community elderly people are included for two sessions of NPB test evaluation for calculation of POCD incidence as normal control to in Z value calculation of POCd incidence to rule out learning effect.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Post Discharge Online Telerehabilitation Program

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic pain consistent with IASP definition.~* Classification as a completer of the Brooks Rehabilitation Pain Rehabilitation Program by attending the expected number of sessions and achieving at least 90% of goals.~* Able to read, write, and understand spoken English fluently.~Exclusion Criteria:~* Any medical condition that would place the participant at risk with performing a home exercise program.~* Inability to see or hear the audio visual device from a distance of at least 5 feet (may use headphones).~* Cognitive impairment or learning barriers preventing appropriate ability to access and navigate the study-related web-site or play the study-related DVD's.~* Lack of regular access to internet service.~* Lack of regular access to an internet connected audio-visual device (e.g., smartphone, computer, tablet, etc) in a location with sufficient space to perform exercises.~* Not familiar with basic internet navigation (i.e. able to locate and access a desired website and use basic within-site navigation tools such as scrolling and clicking on links.~* Currently pregnant (self-reported)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telerehabilitation (Type: EXPERIMENTAL): Participant randomized into the telerehabilitation group will receive verbal and written discharge recommendations from each member of the team as usual. They will also be given a login to the online telerehabilitation platform where they will find the designated flexibility routines which can be accessed from a computer, tablet/slate, or smart phone at any time. Participant will receive electronic reminders via email and/or text message to perform their home program and complete the follow up questionnaires. Other physical therapy exercises may be recommended based on individual patient's need. These exercises will be provided in verbal and written form.
- Usual care (Type: ACTIVE_COMPARATOR): Participants randomized into the usual care group will receive verbal and written discharge recommendations from each member of the team as usual. They will be provided with a copy of the DVD and instructed to practice one of the two routines at least 5 days per week. They will also be given a login to the online platform but will only have access to complete the follow up questionnaires. Participant will receive electronic reminders via email and/or text message to complete the follow up questionnaires. Other physical therapy exercises may be recommended based on individual patient's need. These exercises will be provided in verbal and written form.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent obtained prior to any protocol-specific procedures~* Male and female patients with histologically confirmed squamous cell carcinoma~* At least one site of active malignancy, as demonstrated on the pre-study 18F FDG PET/CT scan performed as part of routine clinical care~* Age \>/= 18 years~* Life expectancy \>/= 3 months~* ECOG Performance score of 0-2~Exclusion Criteria:~* Pregnant or breastfeeding females~* Systemic anti-neoplastic therapy within the 2 weeks prior to the pre-study 18F FDG PET/CT scan until after the 18F FPM PET/CT scan~* Any serious medical condition which the investigator feels may interfere with the procedures or evaluations of the study~* Patients unwilling or unable to comply with protocol or with a history of non-compliance or inability to grant informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- D-18F FPM (Type: EXPERIMENTAL): None
- L-18F FPM (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Abdominoperineal Extra-Elevators Rectal Resection for Cancer: Prone Position vs. Supine Position

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with primary low lying rectal cancer involving or threatening anal sphincter complex as seen in MRI~Exclusion Criteria:~* American Society of Anaesthesiologists classification of Physical Health (ASA) IV patients~* Locally palliative purpose of the operation~* Age \< 18 years~* Preoperative indication for pelvic exenteration~* Pregnancy~* Lack of patients consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supine position (Type: ACTIVE_COMPARATOR): Abdominoperineal resection - perineal time- in supine position
- Prone position (Type: EXPERIMENTAL): Abdominoperineal resection - perineal time- in prone position

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of the Treatment of Erectile Dysfunction (ED) With Extracorporeal Shockwave Therapy (ESWT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Erectile dysfunction for more than 6 months~* Informed consent~* Positive effect of phosphodiesterase type 5 inhibitor (PDE5i)~* IIEF-15 score less than 20~* No neurological disease~* Stable partnership for more than 3 months~* Age 18-75~Exclusion Criteria:~* Total prostatectomy~* Another reason for ED except for vascular disorder~* Clinically significant hematological disease~* Heart stroke, Arrythmia during the last 6 months~* Cancer during the last 5 years~* Intake of antiandrogen~* ED treatment with the last 7 days~* IIEF score higher than, equal to 20~* Previous shockwave treatment

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Shock wave treatment (Type: ACTIVE_COMPARATOR): Shock waves are applied extracorporeally with 0.1 millijoule per square millimeter (mJ/mm2)
- Placebo Shock wave treatment (Type: PLACEBO_COMPARATOR): Shock waves are prohibited to enter the body by placebo stand-off.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility